{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:35:14Z","timestamp":1715906114931},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"DOI":"10.7759\/cureus.60410","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:08:19Z","timestamp":1715854099000},"source":"Crossref","is-referenced-by-count":0,"title":["Spontaneous Hemopericardium Associated With Apixaban Use With Newly Diagnosed Malignancy and Acute Kidney Injury: A Case Report"],"prefix":"10.7759","author":[{"given":"Awss","family":"Shalhoub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar M","family":"Masarweh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref2","article-title":"Direct oral anticoagulants associated hemopericardium","author":"Singh A","year":"2021","unstructured":"Singh A, Verma V, Chaudhary R. Direct oral anticoagulants associated hemopericardium. ACC Journal. 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2021.09.010","article-title":"Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review","volume":"39","author":"Sheikh AB","year":"2022","unstructured":"Sheikh AB, Shah I, Sagheer S, et al.. Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review. Cardiovasc Revasc Med. 2022, 39:73-83. 10.1016\/j.carrev.2021.09.010","journal-title":"Cardiovasc Revasc Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1602","article-title":"Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report","volume":"35","author":"Sigawy C","year":"2015","unstructured":"Sigawy C, Apter S, Vine J, Grossman E. Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report. Pharmacotherapy. 2015, 35:e115-7. 10.1002\/phar.1602","journal-title":"Pharmacotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30021","article-title":"Hemorrhagic pericardial effusion from apixaban use: case report and literature review","volume":"14","author":"Nasir SA","year":"2022","unstructured":"Nasir SA, Babu Pokhrel N, Baig A. Hemorrhagic pericardial effusion from apixaban use: case report and literature review. Cureus. 2022, 14:e30021. 10.7759\/cureus.30021","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1338274","article-title":"The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)","volume":"13","author":"O'connor CT","year":"2017","unstructured":"O'connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: a pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017, 13:725-39. 10.1080\/17425255.2017.1338274","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.143","article-title":"Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents","volume":"96","author":"Harvey RD","year":"2014","unstructured":"Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014, 96:449-57. 10.1038\/clpt.2014.143","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri N","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022, 14:1120. 10.3390\/pharmaceutics14061120","journal-title":"Pharmaceutics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly SJ","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, et al.. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019, 380:1326-35. 10.1056\/NEJMoa1814051","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.620","article-title":"What to do after the bleed: resuming anticoagulation after major bleeding","volume":"2016","author":"Witt DM","year":"2016","unstructured":"Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016, 2016:620-4. 10.1182\/asheducation-2016.1.620","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253060-spontaneous-hemopericardium-associated-with-apixaban-use-with-newly-diagnosed-malignancy-and-acute-kidney-injury-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T10:08:22Z","timestamp":1715854102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253060-spontaneous-hemopericardium-associated-with-apixaban-use-with-newly-diagnosed-malignancy-and-acute-kidney-injury-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.60410","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}